Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-negative status confers therapeutic sensitivity to Bevacizumab, Paclitaxel in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with paclitaxel for reimbursement as a treatment option for the first-line treatment of patients with HER2-negative metastatic breast cancer.
This statement is based on a regulatory approval from the Health Service Executive:
In combination with PACLitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.